MYRIAD GENETICS INCInsider Trading & SEC Form 4 Analysis
Institutional analysis of internal capital flows based on SEC Form 4 filings.
Automated_Intelligence_Report :: MYGN
Algorithmic analysis of recent insider trading activity for MYGN reveals a bullish posture among the C-suite and board members. Based on the latest SEC Form 4 filings, we have tracked capital events executed by 20 distinct corporate insiders. The aggregate nominal exposure during this reporting cycle reached $3.16M.
Market dynamics show a positive net capital flow of $0.66M when isolating open-market purchases versus open-market sales. The trading volume is heavily weighted towards open-market executions, providing a clearer signal of insider conviction regarding current valuation levels compared to option-based equity grants.
From a microstructural perspective, the landscape is fragmented. Phanstiel S. Louise led the buying pressure, while Kumar Rashmi registered the largest single offload of shares. Continuous monitoring of these Tier-1 actors is essential, as their liquidity decisions often precede material corporate events or reflect an informed, asymmetric perspective on the future performance of MYGN.
$3.16M
USD NOMINAL VALUE20
UNIQUE C-SUITE ENTITIES2026.06.11
ISO_8601 FORMATAutomated_Queries :: Frequently Asked Questions
>When was the latest SEC Form 4 filed for MYGN?
The most recent insider transaction on record was filed on 2026.06.11. InsiderAlpha monitors EDGAR filings and updates this terminal as new Form 4 documents are published.
>How many corporate insiders are active in MYGN?
Our dataset currently tracks 20 distinct insiders with reported transactions for MYGN in the active reporting window.
>Is insider buying outweighing selling at MYGN?
Open-market buying volume ($0.72M) currently exceeds selling volume ($0.07M), suggesting net accumulation by insiders.